

Ondrej Kalous

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4225670/publications.pdf>

Version: 2024-02-01

15
papers

1,860
citations

687363

13
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

3544
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 897-907.	4.1	77
2	Proteasome ubiquitin receptor <i>PSMD4</i> is an amplification target in breast cancer and may predict sensitivity to PARPi. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 589-597.	2.8	27
3	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 669-680.	2.5	46
4	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. <i>Clinical Cancer Research</i> , 2014, 20, 3507-3520.	7.0	100
5	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 397-408.	2.5	21
6	Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 3094-3109.	4.1	43
7	Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 509-519.	4.1	66
8	Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1978-1987.	4.1	68
9	Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 7093-7104.	7.0	34
10	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. <i>Breast Cancer Research</i> , 2009, 11, R77.	5.0	1,131
11	557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 175-176.	2.2	0
12	Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity. <i>Clinical Cancer Research</i> , 2008, 14, 533-540.	7.0	53
13	A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 886-897.	4.1	90
14	Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex. <i>Clinical Cancer Research</i> , 2007, 13, 3079-3086.	7.0	58
15	DIMSCAN: A Microcomputer Fluorescence-Based Cytotoxicity Assay for Preclinical Testing of Combination Chemotherapy. , 2005, 110, 139-154.		46